MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?

MapLight Therapeutics' CFO Setia Vishwas sold 36,371 shares worth approximately $1.02 million in May 2026 through a pre-arranged Rule 10b5-1 trading plan. The sale reduced his direct holdings by 9.3%, though he retains 356,256 shares. The article notes this shouldn't be interpreted as a lack of confidence since it was part of a predetermined trading plan. MapLight, a clinical-stage biotech company focused on CNS disorders, has seen its stock gain 70.8% over the past year but continues to report deepening losses as it advances its pipeline.